Maktaba

Item request has been placed!

Item request cannot be made.

Processing Request

Academic Journal

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.

Authors : Kuemmel S; Breast Unit, Kliniken Essen Mitte, Essen, Germany.; Department of Gynecology with Breast Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Subjects: Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/drug therapy ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/pathology ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/genetics

Source: BMC cancer [BMC Cancer] 2024 May 24; Vol. 24 (1), pp. 641. Date of Electronic Publication: 2024 May 24.Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407

Record details

Read Online Read More Add to Saved list

Academic Journal

Chemotherapy-Induced Changes in Plasma Amino Acids and Lipid Oxidation of Resected Patients with Colorectal Cancer: A Background for Future Studies.

Authors : Aquilani R; Department of Biology and Biotechnology 'Lazzaro Spallanzani', University of Pavia, 27100 Pavia, Italy.; Brugnatelli S

Subjects: Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/blood ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/drug therapy ; Colorectal Neoplasms*/Colorectal Neoplasms*/Colorectal Neoplasms*/surgery XELOX; Folfox protocol

Source: International journal of molecular sciences [Int J Mol Sci] 2024 May 13; Vol. 25 (10). Date of Electronic Publication: 2024 May 13.Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067

Record details

Read Online Read More Add to Saved list

Academic Journal

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.

Authors : Wang DS; Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.; Ren C

Subjects: Cetuximab*/Cetuximab*/Cetuximab*/administration & dosage ; Cetuximab*/Cetuximab*/Cetuximab*/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use FOLFOXIRI protocol; Folfox protocol

Source: PLoS medicine [PLoS Med] 2024 May 10; Vol. 21 (5), pp. e1004389. Date of Electronic Publication: 2024 May 10 (Print Publication: 2024).Publisher: Public Library of Science Country of Publication: United States NLM ID: 101231360 Publication Model: eCollection Cited Medium: Internet

Record details

Read Online Read More Add to Saved list

Academic Journal

Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.

Authors : Zhang Y; Department of Oncology, Second Affiliated Hospital of Nanchang University, Nanchang, 330006, P.R. of China.; Jiangxi Key Laboratory of Clinical and Translational Cancer Research, Nanchang, 330006, P.R. of China.

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/pathology ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/mortality

Source: World journal of surgical oncology [World J Surg Oncol] 2024 May 06; Vol. 22 (1), pp. 122. Date of Electronic Publication: 2024 May 06.Publisher: BioMed Central Country of Publication: England NLM ID: 101170544 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7819

Record details

Read Online Read More Add to Saved list

Academic Journal

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.

Authors : Kato K; Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.; Doki Y

Subjects: Ipilimumab*/Ipilimumab*/Ipilimumab*/administration & dosage ; Ipilimumab*/Ipilimumab*/Ipilimumab*/therapeutic use ; Ipilimumab*/Ipilimumab*/Ipilimumab*/adverse effects

Source: Cancer medicine [Cancer Med] 2024 May; Vol. 13 (9), pp. e7235.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.

Authors : Qiao L; State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Centre, Guangzhou, China.; Department of Liver Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China.

Subjects: Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/drug therapy ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/mortality ; Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/Carcinoma, Hepatocellular*/therapy

Source: Cancer medicine [Cancer Med] 2024 May; Vol. 13 (9), pp. e7236.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial.

Authors : Yu TT; Department of Radiation Oncology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.; Hu X

Subjects: Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/drug therapy ; Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/mortality ; Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/Small Cell Lung Carcinoma*/radiotherapy

Source: Cancer medicine [Cancer Med] 2024 Apr; Vol. 13 (8), pp. e7215.Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

Long-term Musculoskeletal Consequences of Chemotherapy in Pediatric Mice.

Authors : Huot JR; Department of Anatomy, Cell Biology and Physiology, Indiana University School of Medicine, Indianapolis, IN, 46202 USA.; Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, 46202 USA.

Subjects: Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/adverse effects; Camptothecin/Camptothecin/Camptothecin/*analogs & derivatives; Animals IFL protocol

Source: Function (Oxford, England) [Function (Oxf)] 2024 Mar 07; Vol. 5 (3), pp. zqae011. Date of Electronic Publication: 2024 Mar 07 (Print Publication: 2024).Publisher: Oxford University Press Country of Publication: England NLM ID: 101770668 Publication Model: eCollection Cited Medium: Internet ISSN:

Record details

Read Online Read More Add to Saved list

Academic Journal

Comparison of efficacy of neoadjuvant chemotherapy with gemcitabine plus cisplatin versus docetaxil, cisplatin, plus fluorouracil in locally advanced nasopharyngeal carcinoma.

Authors : Rehman A; Department of Medical Oncology, Jinnah Medical Postgraduate Center (JMPC), Karachi, Pakistan.; Haider G

Subjects: Cisplatin*/Cisplatin*/Cisplatin*/administration & dosage ; Cisplatin*/Cisplatin*/Cisplatin*/therapeutic use ; Gemcitabine*

Source: Pakistan journal of pharmaceutical sciences [Pak J Pharm Sci] 2024 Mar; Vol. 37 (2), pp. 377-383.Publisher: Faculty of Pharmacy, University of Karachi Country of Publication: Pakistan NLM ID: 9426356 Publication Model: Print Cited Medium: Internet

Record details

Read Online Read More Add to Saved list

Academic Journal

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients.

Authors : Wimmer K; Department of General Surgery, Division of Visceral Surgery and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria.; Austrian Breast & Colorectal Cancer Study Group (ABCSG), Vienna, Austria.

Subjects: Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/pharmacology ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/drug therapy ; Breast Neoplasms*/Breast Neoplasms*/Breast Neoplasms*/pathology

Source: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Nov 14; Vol. 42 (1), pp. 300. Date of Electronic Publication: 2023 Nov 14.Publisher: BioMed Central Country of Publication: England NLM ID: 8308647 Publication Model: Electronic Cited Medium: Internet ISSN: 1756-9966

Record details

Read Online Read More Add to Saved list

Search Results

Your Filters

Chemotherapy-Induced Changes in Plasma Amino Acids and Lipid Oxidation of Resected Patients with Colorectal Cancer: A Background for Future Studies.

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.

Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial.

Regorafenib with immunotherapy versus regorafenib alone as second-line treatment for hepatocellular carcinoma: A multicenter real-world study.

Six versus four or five cycles of first-line etoposide and platinum-based chemotherapy combined with thoracic radiotherapy in patients with limited-stage small-cell lung cancer: A propensity score-matched analysis of a prospective randomized trial.

Long-term Musculoskeletal Consequences of Chemotherapy in Pediatric Mice.

Comparison of efficacy of neoadjuvant chemotherapy with gemcitabine plus cisplatin versus docetaxil, cisplatin, plus fluorouracil in locally advanced nasopharyngeal carcinoma.

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients.